ArticleAmerican journal of translational research2025
Verapamil and venlafaxine combined as an effective and well-tolerated adjunct for cancer pain management.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo evaluate the efficacy of combining verapamil and venlafaxine in cancer pain management.
methodsThis retrospective study included 203 patients with cancer pain treated between March 2022 and March 2025. The patients were divided into a control group (n = 98) receiving verapamil alone and an observation group (n = 105) receiving a combination of verapamil and venlafaxine. Pain relief was assessed using the Numeric Rating Scale (NRS), Visual Analogue Scale (VAS), and Brief Pain Inventory (BPI) at baseline, and post-treatment 2 and 4 weeks. Secondary measures included anxiety and depression (Hospital Anxiety and Depression Scale [HADS] and Generalized Anxiety Disorder 7 [GAD-7] scale), quality of life (Karnofsky Performance Status [KPS] and Quality of Life [QOL] scale), and adverse reactions.
resultsThe observation group had higher rates of significant pain relief (42.9% vs 18.4%) and overall pain relief efficiency (81.0% vs 53.1%; P < 0.001 for both) compared with the control group. At post-treatment 2 and 4 weeks, the observation group demonstrated greater reductions in NRS, VAS, and BPI pain scores, lower anxiety and depression scores, and higher KPS and quality-of-life scores (all P < 0.001). Adverse events were comparable between the two groups (P > 0.05).
conclusionCompared with verapamil alone, combined therapy of verapamil and venlafaxine significantly relieves pain, improves psychological outcomes, and enhance patients' quality of life without increasing adverse events. These findings support its potential as an effective and well-tolerated adjunctive strategy for cancer pain management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.